SCHEMBL589078

SCHEMBL589078

COc1ccc(C#N)c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 1.00
IMPDH1 P20839 1/20 1.00
IDO1 P14902 1/20 0.52
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
USP2 O75604 1/20 0.52
EP300 Q09472 1/20 0.50
KAT8 Q9H7Z6 1/20 0.50
CYP3A4 P08684 1/20 0.48
ESRRA P11474 1/20 0.48
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
NQO1 P15559 1/20 0.45
AR P10275 5/20 0.45
PGR P06401 2/20 0.45
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
NR3C1 P04150 1/20 0.43
NR3C2 P08235 1/20 0.43
MAPT P10636 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2987592 0.88 IMPDH2 (0.79) IMPDH2IMPDH1IDO1ALDH1A1KDM4E
SCHEMBL3082889 0.80 IMPDH2 (0.67) IMPDH2IMPDH1IDO1ALDH1A1EP300
SCHEMBL11818532 0.80 IMPDH2 (0.67) IMPDH2IMPDH1IDO1ALDH1A1KDM4E
SCHEMBL29489135 0.80 IMPDH2 (0.64) IMPDH2IMPDH1ALDH1A1KDM4EAR
SCHEMBL419307 0.80 IDO1 (0.73) IMPDH2IMPDH1IDO1ALDH1A1KDM4E
SCHEMBL151936 0.80 IMPDH2 (0.64) IMPDH2IMPDH1ALDH1A1KDM4EAR
SCHEMBL29380721 0.80 IDO1 (0.73) IMPDH2IMPDH1IDO1ALDH1A1KDM4E
SCHEMBL19435574 0.79 IMPDH2 (0.64) IMPDH2IMPDH1ALDH1A1KDM4EUSP2
SCHEMBL15805518 0.79 IMPDH2 (0.64) IMPDH2IMPDH1ALDH1A1KDM4EUSP2
SCHEMBL11819764 0.78 IMPDH2 (0.65) IMPDH2IMPDH1IDO1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12163968-B2 Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers BIO-RAD LABORATORIES, INC. (US) 2024-12-10 US claimed
US-9293711-B2 Organic semiconductor formulations POLYERA CORPORATION (US) 2016-03-22 US claimed
US-20140042369-A1 Organic Semiconductor Formulations USINVEST LLC 2014-02-13 US claimed
US-20250129016-A1 PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-04-24 US disclosed
US-12163968-B2 Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers BIO-RAD LABORATORIES, INC. (US) 2024-12-10 US disclosed
CN-118251445-A Cyclic organosiloxane containing imide bond and polymerizable unsaturated bond and curable resin composition containing the same 信越化学工业株式会社 2024-06-25 CN disclosed
CN-116490555-A Copper-clad laminate and printed circuit board 三菱瓦斯化学株式会社 2023-07-25 CN disclosed
CN-116490350-A Resin composition, prepreg, resin sheet, metal foil-clad laminate, and printed wiring board 三菱瓦斯化学株式会社 2023-07-25 CN disclosed
EP-4208021-A1 PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS Bio-Rad Laboratories, Inc. (US) 2023-07-12 EP disclosed
WO-2022051443-A1 PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS BIO-RAD LABORATORIES, INC. (US) 2022-03-10 WO disclosed
US-20220065878-A1 PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS BIO-RAD LABORATORIES, INC. 2022-03-03 US disclosed
WO-1999009978-A1 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed
WO-1997021716-A1 NAPHTHYL GLYOXAMIDES AS sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1997-06-19 WO disclosed
EP-0779273-A1 Naphthyl glyoxamides as sPLA2 inhibitors ELI LILLY AND COMPANY (US) 1997-06-18 EP disclosed
EP-0315959-B1 Quinoxaline compounds and their preparation and use NOVO NORDISK AS (DK) 1994-03-02 EP disclosed
US-5026704-A Neuroleptic agent, quisqualate-antagonist NOVO NORDISK A/S (DK) 1991-06-25 US disclosed
US-4948794-A NEUROLEPTIC AGENTS A/S FERROSAN (DK) 1990-08-14 US disclosed
EP-0315959-A2 Quinoxaline compounds and their preparation and use NOVO NORDISK A/S (DK) 1989-05-17 EP disclosed
US-4593025-A A 2-naphthyl-4,6-diamino-s-triazine compound NIPPON SHINYAKU CO., LTD. (JP) 1986-06-03 US disclosed
US-4554275-A Triazine derivatives NIPPON SHINYAKU CO., LTD. (JP) 1985-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129016-A1 PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF RCC2, PPOX, FTO IMPDH2 3688/4885IMPDH1 3441/4885IDO1 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.